Evgen Pharma(GB:TCF)
GBX 0.170.00 (0.00%)
GB:TCF
Evgen Pharma stock drug pipeline
GBX 0.17
At close:0.00 (0.00%)
Want to see GB:TCF full AI Analyst Report?
Evgen Pharma (TCF) Drug Pipeline
4 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Fulvestrant, Tamoxifen, Sfx-01, Aromatase Inhibitors | Breast Neoplasm | Phase II | Completed | SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer | Nov 15, 2016 | ― |
| Sfx-01 | Subarachnoid Hemorrhage, Spontaneous | Phase II | Completed | SFX-01 After Subarachnoid Haemorrhage | Nov 16, 2015 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Fulvestrant, Tamoxifen, Sfx-01, Aromatase Inhibitors | Phase II | Breast Neoplasm | Completed | SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer | Nov 15, 2016 | ― |
| Sfx-01 | Phase II | Subarachnoid Hemorrhage, Spontaneous | Completed | SFX-01 After Subarachnoid Haemorrhage | Nov 16, 2015 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Evgen Pharma (GB:TCF) have in its pipeline
Evgen Pharma GB:TCF is currently developing the following drugs: Fulvestrant, Tamoxifen, Sfx-01, Aromatase Inhibitors, Sfx-01. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

